Oleclumab: Difference between revisions

Latest revision as of 23:41, 11 December 2024

Oleclumab

Oleclumab is a monoclonal antibody that targets the CD73 enzyme, which is involved in the adenosine pathway. This pathway plays a significant role in the suppression of the immune response in the tumor microenvironment. By inhibiting CD73, oleclumab aims to enhance the immune system's ability to attack cancer cells.

Mechanism of Action[edit]

CD73 is an ecto-5'-nucleotidase that catalyzes the conversion of extracellular AMP to adenosine. Adenosine is an immunosuppressive molecule that can inhibit the activity of various immune cells, including T cells and natural killer cells. By blocking CD73, oleclumab reduces the production of adenosine, thereby potentially enhancing anti-tumor immunity.

Clinical Development[edit]

Oleclumab is currently being investigated in clinical trials for its efficacy and safety in treating various types of cancer, including non-small cell lung cancer (NSCLC) and pancreatic cancer. It is often studied in combination with other therapies, such as immune checkpoint inhibitors, to assess synergistic effects.

Potential Benefits[edit]

The inhibition of CD73 by oleclumab may lead to:

Enhanced T cell activation and proliferation.
Increased infiltration of immune cells into the tumor microenvironment.
Improved efficacy of other immunotherapies.

Side Effects[edit]

As with many monoclonal antibodies, oleclumab may cause side effects, which can include:

Infusion-related reactions.
Fatigue.
Nausea.
Immune-related adverse events.

Research and Future Directions[edit]

Ongoing research is focused on understanding the full potential of oleclumab in cancer therapy, including its role in combination regimens and its effects on different tumor types. Researchers are also exploring biomarkers that may predict response to oleclumab treatment.

Also see[edit]

@@ Line 1: / Line 1: @@
-<languages /><translate>
+Oleclumab
-A monoclonal antibody against the ectoenzyme CD73 (cluster of differentiation 73), also known as 5'-nucleotidase (5'-NT; ecto-5'-nucleotidase) with potential antineoplastic activity. Upon administration, oleclumab targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells. This also activates macrophages, and reduces both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein upregulated on a number of cancer cell types, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.
-</translate>
+Oleclumab is a monoclonal antibody that targets the CD73 enzyme, which is involved in the adenosine pathway. This pathway plays a significant role in the suppression of the immune response in the tumor microenvironment. By inhibiting CD73, oleclumab aims to enhance the immune system's ability to attack cancer cells.
-{{stubd}}
+==Mechanism of Action==
+CD73 is an ecto-5'-nucleotidase that catalyzes the conversion of extracellular AMP to adenosine. Adenosine is an immunosuppressive molecule that can inhibit the activity of various immune cells, including T cells and natural killer cells. By blocking CD73, oleclumab reduces the production of adenosine, thereby potentially enhancing anti-tumor immunity.
+==Clinical Development==
+Oleclumab is currently being investigated in clinical trials for its efficacy and safety in treating various types of cancer, including non-small cell lung cancer (NSCLC) and pancreatic cancer. It is often studied in combination with other therapies, such as immune checkpoint inhibitors, to assess synergistic effects.
+==Potential Benefits==
+The inhibition of CD73 by oleclumab may lead to:
+* Enhanced T cell activation and proliferation.
+* Increased infiltration of immune cells into the tumor microenvironment.
+* Improved efficacy of other immunotherapies.
+==Side Effects==
+As with many monoclonal antibodies, oleclumab may cause side effects, which can include:
+* Infusion-related reactions.
+* Fatigue.
+* Nausea.
+* Immune-related adverse events.
+==Research and Future Directions==
+Ongoing research is focused on understanding the full potential of oleclumab in cancer therapy, including its role in combination regimens and its effects on different tumor types. Researchers are also exploring biomarkers that may predict response to oleclumab treatment.
+==Also see==
+* [[Monoclonal antibody therapy]]
+* [[Immunotherapy]]
+* [[Cancer immunotherapy]]
+* [[CD73]]
+* [[Adenosine pathway]]
+{{Monoclonal antibodies}}
+{{Cancer treatment}}
+[[Category:Monoclonal antibodies]]
+[[Category:Cancer treatments]]
+[[Category:Immunotherapy]]